Aardvark Therapeutics Inc... (AARD)
| Bid | 8 |
| Market Cap | 192.46M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -1.25 |
| PE Ratio (ttm) | -7.2 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 10.35 |
| Volume | 37,076 |
| Avg. Volume (20D) | 200,244 |
| Open | 9.32 |
| Previous Close | 9.24 |
| Day's Range | 8.69 - 9.10 |
| 52-Week Range | 8.60 - 19.58 |
| Beta | 0.00 |
About AARD
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndr...
Analyst Forecast
According to 4 analyst ratings, the average rating for AARD stock is "Buy." The 12-month stock price forecast is $25.5, which is an increase of 183.33% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
U.S. IPO Weekly Recap: Cement And Cystic Fibrosis Drugs Lead A 6 IPO WeekTwo sizable companies and a handful of small Asian issuers were listed in the US this past week. Four small Asia-based issuers also went public in the US - EPWK Holdings, FBS Global, Plutus Financial ...
1 month ago · seekingalpha.com
Aardvark Therapeutics Starts $100 Million IPO Effort For Hunger TreatmentsAardvark Therapeutics aims to raise $100 million in an IPO to fund its clinical-stage biopharma treatments for metabolic conditions, including Prader-Willi syndrome. Its lead candidate ARD-101, target...